行情

OPGN

OPGN

OpGen
NASDAQ

实时行情|Nasdaq Last Sale

6.88
+0.18
+2.69%
盘后: 7.10 +0.22 +3.20% 19:14 09/20 EDT
开盘
6.73
昨收
6.70
最高
6.91
最低
6.39
成交量
10.78万
成交额
--
52周最高
48.20
52周最低
4.204
市值
607.01万
市盈率(TTM)
-0.0110
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

OPGN 新闻

  • Gaithersburg biotech regains compliance with Nasdaq amid merger
  • American City Business Journals.2天前
  • OpGen updates on Curetis collaboration
  • Seeking Alpha - Article.3天前
  • OpGen Reports Curetis Announced Its Ares Genetics Unit Entered Multi-Phase Collaboration With Undisclosed Leading Global In Vitro Diagnostics Corp. To Jointly Develop Diagnostic Solutions For Infectious Disease Testing
  • Benzinga.3天前
  • OpGen Provides update on Curetis Group’s R&D Collaboration
  • GlobeNewswire.3天前

更多

所属板块

生物技术和医学研究
+0.62%
制药与医学研究
+0.95%

热门股票

名称
价格
涨跌幅

OPGN 简况

OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company's high-resolution DNA tests are marketed under the Acuitas trade name.
展开

Webull提供OpGen Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。